Pielotax®
RESEARCH RESULTS
As a result of the studies, it was found that the use of PIELOTAX® helped to smooth the clinical
manifestations of gouty nephropathy in 78% of cases. However, the most revealing was the data
of laboratory research. While taking the drug, the activation of the metabolism of renal tissues was
observed, accompanied by an increase in the secretory function of the kidneys, which is reflected in
the dynamics of the biochemical parameters of the patients’ blood (Table 2).
As can be seen from the data shown in Table 2, in the control group, after treating patients with
conventional methods, an improvement in blood biochemical parameters, reflecting renal function,
was observed. However, these indicators did not reach normal values. In patients of the primary
group, blood biochemical parameters were close to normal values for men and women. Thus,
the residual nitrogen in the control group was on average 35.4 ± 0.8 mmol/l before treatment,
and after treatment - 30.5 ± 0.6 mmol/l (p <0.05), however, in patients of the primary group, this
indicator decreased to 27.1 ± 0.4 mmol/l, which is significantly lower compared to the indicator in
the control group and corresponds to the lower limit of the norm (28.6 mmol/l). The same trend
can be traced in the dynamics of the urea content in the blood: a decrease in the initially increased
indicator is observed in patients of both groups. However, in the primary group, the indicator was
9.2 ± 0.3 mmol/l, which brings its normal value closer to its average value (8.3 mmol/l). Changes in
the content of uric acid are also characteristic: in both men and women of the primary group, after
further use of the study drug, the indicators returned to normal - in men, the content of uric acid
decreased to 0.44 ± 0.02 mmol/l (in the control group, 0.56 ± 0.01 mmol/l, the norm is up to 0.50
mmol/l); in women of the primary group - up to 0.37 ± 0.03 mmol/l (in the control group 0.48 ±
0.02 mmol/l, the norm is up to 0.40 mmol/l).
Influence of PIELOTAX®on the biochemical parameters of the blood of Table 2
patients with gouty nephropathy.
Indicators Before Treatment After Treatment
Control Group Primary Group Control Group Primary Group
Residual nitrogen, (mmol/l) 35,4±0,8 34,1±0,7 30,5±0,6* 27,1±0,4*#
Residual nitrogen, (mmol/l) 14,7±0,5 13,8±0,6 11,8±0,5* 9,2±0,3*#
Uric acid, (mmol/l)
- women 0,57±0,01 0,55±0,02 0,48±0,02* 0,37±0,03*#
- men 0,75±0,03 0,78±0,04 0,56±0,01* 0,44±0,02*#
* - p <0.05 compared with the indicator in the same group before treatment.
# - p <0.05 compared to the same indicator in the control group
Thus, the results obtained indicate the therapeutic effectiveness of PIELOTAX®and the advisability
of its use in the complex treatment of patients with gouty nephropathy and other diseases associated
with impaired renal function.
PIELOTAX®does not cause side effects, complications, or drug dependence.
PIELOTAX®can be used for therapeutic and prophylactic purposes in the form of a biologically active
food supplement combined with any means of symptomatic and pathogenetic therapy used to treat
patients with gouty nephropathy and other kidney diseases.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.